PZ-1922 is a Triple-Acting 5‑HT6R/5-HT3R Antagonist and MAO‑B Reversible Inhibitor. PZ-1922 reversed scopolamine-induced cognitive deficits in the novel object recognition test. Furthermore, it displayed superior pro-cognitive properties compared to intepirdine (a 5-HT6R antagonist) in the AD model, which involved intracerebroventricular injection of an oligomeric solution of amyloid-β peptide (oAβ) in the T-maze test in rats. PZ-1922, but not intepirdine, restored levels of biomarkers characteristic of the debilitating effects of oAβ.
MedKoo Cat#: 125150
Name: PZ-1922
CAS#: N/A
Chemical Formula: C22H21ClN4
Exact Mass: 376.1500
Molecular Weight: 376.89
Elemental Analysis: C, 70.11; H, 5.62; Cl, 9.41; N, 14.87
The following data is based on the product molecular weight 376.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
